The London Clinic, a private hospital and charity on Harley Street, is offering adult patients with diffuse large B-cell lymphoma – an aggressive form of blood cancer – a new form of immunotherapy called CAR-T cell therapy.
The CAR-T (chimeric antigen receptor T-cell) cell therapy works through the collection of immune cells (T cells) from the blood of patients.
These T-cells are then genetically modified to destroy cancer cells in a laboratory and given back to the patient.
The therapy is for patients who have no other treatment options having failed conventional chemotherapy.
A phase 2 clinical trial of 111 patients showed positive outcomes, with 52% of patients living for 18 months after treatment. Real-world data is at an early stage.
LCAR-T therapy is approved by the UK’s National Institute for Health and Care Excellence (NICE).
Professor John Gribben, who is leading the treatment at The London Clinic, said CAR-T cell therapy is an exciting advancement in the treatment of blood cancers, offering a final treatment option for patients who haven’t had the result they need from conventional therapy.
“So far, this treatment is showing promising outcomes for many patients, letting them return to normal lives with their families and loved-ones,” he added.